Immix Biopharma, Inc.

NASDAQ:IMMX

Biotechnology

Healthcare
$7.11 +0.99%

+$0.09 today

Market cap
$595.91M
Beta
0.10
P/E (TTM)
-10.1
EPS (TTM)
-$0.91
52W Low $1.94High $11.61

Volume 0.88M

Average 1.07M

IMMX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Immix Biopharma, Inc.NASDAQ: IMMX

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $4.82M rose 78.1% year over year, ahead of the +34.6% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 6.6% from the prior quarter. Over 3 fiscal years it compounded at +50.4% a year.

Context

  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +20.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.82M-6.6% QoQ
Last fiscal yearDec 2025
$13.7M+20.3% YoY
LTMMar 2026
$15.81M+34.6% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+78.1%-100.0%-178.1 pp
1 year+20.3%-100.0%-120.3 pp
3-year CAGR+50.4%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
13.7M USD
Year-over-year change
+20.3%
4-year CAGR
+82.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How IMMX compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +34.6% is the 4th highest of 11, against a peer median of +24.4%.
  • Over three fiscal years its annual growth of +50.4% compares with a peer median of +4.4%.
IMMX Competitors
Selling, General & Admin for IMMX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$106M USD-7.8%+1.9%90.6%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$78.21M USD+57.0%+11.6%11.1%
ABVXAbivax S.A.FY2025€72.87M EUR+87.3%+113.4%—
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$51.3M USD+21.7%+17.2%45802.7%
MGNXMacroGenics, Inc.LTM Mar 2026$38.15M USD-27.9%-12.7%24.3%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$31.1M USD-1.0%-11.4%87.5%
IMUXImmunic, Inc.LTM Mar 2026$23.53M USD+30.1%+11.7%—
NBPNovaBridge BiosciencesLTM Sep 2025CN¥21.46M CNY+128.2%-71.8%—
IMMXImmix Biopharma, Inc.LTM Mar 2026$15.81M USD+34.6%+50.4%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$13.02M USD+27.1%+2.6%2479.6%
IMMPImmutep LimitedFY2025A$8.64M AUD-2.4%+6.2%171.4%
Peer median (excluding IMMX) —+24.4%+4.4%90.6%

Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000364.5K
Gross Profit0000(364.5K)
Gross Margin—————
Research & Development126.53K4.2M8.74M11.29M16.26M
Selling, General & Admin1.23M4.02M7.41M11.38M13.7M
Operating Expenses1.35M8.22M16.14M22.67M26.85M
Depreciation & Amortization2.47K2.14K5.47K115.39K364.5K
EBITDA(24.2M)(8.22M)(15.56M)(21.54M)(29.04M)
EBITDA Margin—————
Operating Income(1.35M)(8.22M)(16.14M)(22.67M)(27.21M)
Operating Margin—————
Interest Income00572.01K1.02M555.53K
Interest Expense179.85K497000
Other Income / Expenses(23.03M)(497)572.01K1.02M(2.19M)
Income Before Tax(24.38M)(8.22M)(15.57M)(21.66M)(29.4M)
Pre-Tax Margin—————
Income Tax Expense6.01K10.27K26.42K41.04K37.72K
Net Income(24.38M)(8.23M)(15.43M)(21.61M)(29.44M)
Net Margin—————
EPS (Basic)(6.64)(0.59)(0.89)(0.76)(0.89)
EPS (Diluted)(6.64)(0.59)(0.89)(0.76)(0.89)
Weighted Avg Shares3.67M13.89M17.34M28.29M32.97M
Weighted Avg Shares (Diluted)3.67M13.89M17.34M28.29M32.97M

Immix Biopharma, Inc.

NASDAQ:IMMX

Intrinsic Alpha fair value

Locked

Current Price

$7.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.